Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor

A heart disease, isoform technology, applied in cardiovascular system diseases, medical preparations containing active ingredients, peptide/protein components, etc., can solve coronary artery restenosis, intimal thickening and other problems

Inactive Publication Date: 2010-12-22
VIROMED CO LTD
View PDF10 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, intimal thickening (e.g. coronary restenosis) is a serious problem when angioplasty is used

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor
  • Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor
  • Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0174] Embodiment 1: Construction of plasmid

[0175] The pCK vector can utilize the human cytomegalovirus (HCMV) promoter to drive gene expression and has been described previously (Lee et al., Biochem. Biophys. Res. Commun. 272:230 (2000); WO 2000 / 040737).

[0176] pCK-VEGF165 was constructed by inserting the VEGF165 cDNA into the pCK vector and has been described previously (Lee et al., Biochem. Biophys. Res. Commun. 272:230 (2000); WO 2000 / 040737).

[0177] pCK-cHGF contains the encoded HGF under the control of the HCMV promoter 728 and has been described previously (US 2005 / 0079581).

[0178] pCK-dHGF contains the encoded HGF under the control of the HCMV promoter 723 cDNA and has been described previously (PCT / KR03 / 00548).

[0179] pCK-HGF-X7 contains a hybrid HGF cDNA (SEQ ID NO: 9) designed to express two HGF isoforms simultaneously inserted into the pCK vector and has been described previously (US 2005 / 0079581 ).

Embodiment 2

[0180] Example 2: Effects of HGF on Cell Migration and Proliferation

[0181] The purpose of this study was to evaluate the effect of HGF on cell migration and proliferation in vitro.

[0182] 1. Materials and Methods

[0183] (1) Preparation of HGF protein

[0184] Using FuGENE6 TM (Roche Diagnostics, Germany) pCK-HGF-X7 was transfected into 293T cells. pCK, pCK-cHGF and pCK-dHGF were used as controls. Two days after transfection, the culture supernatant containing HGF protein was obtained, and the amount of HGF was measured by human HGF ELISA (R&D Systems, MN, USA) according to the manufacturer's recommendation.

[0185] (2) Cell migration assay

[0186] Evaluation of the effect of HGF on human umbilical vein endothelial cells (HUVEC, Agiolab Co., Ltd., ALO1-0122S), mouse skeletal muscle myoblasts (C2C12, ATCC No. CRL-1772) and rats in a modified Boyden chamber assay Effects on migration of cardiac myoblasts (H9C2, ATCC No. CRL-1446). Inserts of 24-well transwell cell...

Embodiment 3

[0193] Example 3: Efficacy Evaluation of HGF in Rat Ischemic Heart Disease Model

[0194] The aim of this study was to evaluate the cardioprotective effect of intramyocardial injection of HGF in a rat model of ischemic heart disease. The experimental steps are shown in Figure 5 middle.

[0195] 1. Materials and Methods

[0196] (1) animals

[0197] Upon arrival, 38 Sprague-Dawley rats (male, 12 weeks old, 350-400 g, SLC) were given food and water ad libitum and allowed to rest for 7 days before surgery.

[0198] (2) Myocardial infarction model

[0199] To analyze the drug effect of HGF in this study, a rat ischemic heart disease model, which is one of the widely used pathological models of CAD, was used. Rats were anesthetized by intramuscular injection of xylazine (5 mg / kg) followed by ketamine (50 mg / kg). After disinfection with 95% alcohol and iodine, the chest was covered with sterile surgical gauze, exposing only the incision area, thereby providing completely ster...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods for treating or preventing cardiac conditions in a subject comprising administering to the subject two or more isoforms of hepatocyte growth factor (HGF). The present invention further relates to methods for promoting endothelial cell growth in a blood vessel comprising administering to the blood vessel two or more isoforms of hepatocyte growth factor (HGF). In one embodiment the two or more isoforms of HGF are administered as one or more polynucleotides encoding the isoforms.

Description

technical field [0001] The present invention relates to a method of treating or preventing a cardiac disorder in a subject comprising administering to said subject two or more isoforms of hepatocyte growth factor (HGF). The invention also relates to a method of promoting the growth of endothelial cells in a blood vessel comprising administering two or more isoforms of hepatocyte growth factor (HGF) to said blood vessel. In one embodiment, the two or more isoforms of HGF are administered as one or more polynucleotides encoding the isoforms. Background technique [0002] HGF is a glycoprotein bound to heparin, also known as diffusion factor or hepatopoietin A. HGF, originally identified as a potent hepatotrophic growth factor (Nakamura et al., Nature 342:440 (1989)), is a heparin-binding protein from mesenchymal cells that has multiple Biological effects such as mitogenicity, motogenesis and morphogenesis. The gene encoding HGF is located on chromosome 7q21.1, contains 18 e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61K31/7088A61P9/10
CPCA61K38/1833A61K31/70A61P43/00A61P9/00A61P9/10
Inventor 金锺默金水晶韩熊
Owner VIROMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com